JP2023501869A - Drug in liquid form (mutant) for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 - Google Patents

Abstract

The present invention provides a liquid biomolecular agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, which human adenovirus serotype 26 or E1 and E3 regions are deleted. 5 recombinant strain genome and incorporating an expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3; Agents containing a single active ingredient comprising either an expression vector comprising the genome of a recombinant strain of type 25 and incorporating an expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, or SEQ ID NO: 3 . A recombinant strain of human adenovirus serotype 26 may contain the ORF6-Ad26 region replaced by ORF6-Ad5. The buffered solution of the drug in liquid form contains, by weight percent: 0.1831 to 0.3432 Tris; 0.3313 to 0.6212 sodium chloride; 3.7821 to 7.0915 sucrose; 0.0154 0.0029-0.0054 EDTA; 0.0378-0.0709 polysorbate-80; 0.0004-0.0007 ethanol 95%; and until full. Water of. The drug can be administered by intranasal and/or intramuscular routes. The present invention promotes humoral and cell-mediated immune responses against the SARS-CoV-2 virus among a broad spectrum of people.

Description

FIELD OF THE INVENTION The present invention relates to biotechnology, immunology and virology. The claimed agents can be used for the prevention of disease caused by severe acute respiratory syndrome virus SARS-CoV-2.

BACKGROUND OF THE INVENTION The coronavirus (COVID-19) disease outbreak that began in the People's Republic of China at the end of 2019 spread worldwide within months, posing an unprecedented challenge to modern public health systems. Currently, the number of COVID-19 cases has exceeded 105 million and over 2.3 million people have died.

The disease-causing agent is the single-stranded RNA virus SARS-CoV-2, which belongs to the beta-CoV lineage of the Coronaviridae family.

Coronavirus infections are transmitted from person to person by respiratory droplets, dust particles, and contact. The average incubation period is 5-6 days, after which initial symptoms of the disease appear. Common symptoms of COVID-19 include fever, dry cough, shortness of breath, and fatigue. Pharyngitis, joint pain, runny nose, and headache have also been reported as less common symptoms. However, the clinical course of the disease is characterized by varying severity from asymptomatic cases to severe acute respiratory syndrome and death.

The rapid geographic spread and high mortality rate of SARS-CoV-2 has created an urgent need to develop effective drugs to prevent disease caused by this virus. Therefore, the development of a safe and effective vaccine for SARS-CoV-2 is now recognized as a top global priority.

Within a year of the beginning of the pandemic, variants of COVID-19 vaccine candidates were proposed by multiple pharmaceutical companies.

The Pfizer pharmaceutical company, in collaboration with the BioNTech biocompany, has developed a vaccine known as BNT162b2 (todinameran). It is based on modified mRNA encoding the mutant S protein of SARS-CoV-2 embedded in lipid nanoparticles. The vaccination regimen requires two injections 21 days apart (F.P. Polack et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383: 2603-2615).

A Moderna pharmaceutical company and the United States National Institute of Allergy and Infectious Diseases (NIAID) jointly developed the mRNA-1273 vaccine. Its active component is the mRNA encoding the SARS-CoV-2 mutant S protein encased in a lipid shell. According to the immunization regimen, the vaccine must be given in two doses, 28 days apart (L. A. Jackson et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med 2020; 383 : 1920-1931).

The University of Oxford, in collaboration with AstraZeneca plc, has developed a viral vector vaccine ChAdOx1 nCoV-19 (AZD1222). Its active component is the chimpanzee adenovirus ChAdOx1 encoding the codon-optimized full-length S protein sequence of the SARS-CoV-2 virus with the human tissue plasminogen activator leader sequence (GenBank MN908947). According to the immunization regimen, the vaccine must be given in two doses 28 days apart (M. Voysey et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2 : an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. The Lancet. Vol. 397, Issue 10269, P99-111, 2021).

CanSino has developed a viral vector vaccine against COVID-19 based on replication-deficient human adenovirus type 5 (Ad5) expressing the SARS-CoV-2 full-length S-glycoprotein. This is a single dose regimen vaccine (GenBankYP_009724390) (Feng-Cai Zhu et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 2 trial. The Lancet. Vol. 369, Issue 10249, P479-488, 2020).

A research team from Johnson & Johnson's Janssen Pharmaceutical Companies, in collaboration with Beth Israel Deaconess Medical Center, has developed several vaccine candidates using Janssen's AdVac(R) technology platform. Based on the results of safety and efficacy studies, vaccine candidate Ad26. COV2. S(Ad26COVS1) was selected. The vaccine is based on a recombinant E1/E3-deleted adenovirus serotype 26 vector containing the SARS-CoV-2 viral S protein gene with a furin cleavage site mutation and two stabilizing praline mutations . Two immunization regimens are currently being tested: the vaccine is given as a single dose or as two doses 8 weeks apart (J. Sadoff et al. Interim Results of a Phase 1-2a Trial of Ad26. COV2.S Covid-19 Vaccine. N Engl J Med, 2021 Jan 13. DOI: 10.1056 / NEJMoa2034201).

It should therefore be noted that the majority of COVID-19 vaccines require a two-dose regimen.

Each of the vaccines mentioned above has its advantages and disadvantages. Therefore, mRNA vaccines have less severe side effects. However, mRNA vaccines are less immunogenic compared to viral vector vaccines. Moreover, RNA is more fragile and sensitive to storage conditions.

Recombinant viral vector vaccines achieve high immunogenicity. However, a disadvantage of this type of vaccine is the potential to induce an immune response to the vector portion, making revaccination more difficult. Additionally, adenoviruses are circulating in the human population, so some people may have pre-existing immunity to these viruses. Other mammalian adenovirus-based expression vectors are used to solve the problem of pre-existing immunity, but such vectors have a lower ability to enter human cells, further reducing vaccine efficacy.

Selected as a prototype by the authors of the claimed invention, patent RF No. 2731342 (published on 01.09.2020) there is a technical solution. The following variants of medicaments for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 are known from this patent:
- an expression vector based on the genome of recombinant human adenovirus serotype 26 in which the E1 and E3 regions have been deleted and the ORF6-Ad26 region has been replaced by ORF6-Ad5, comprising SEQ ID NO: 1, sequence No. 2, a recombinant human adenovirus serotype 5 containing a component 1 containing a drug in the form of an expression vector incorporating an expression cassette selected from SEQ ID No. 3 and having deletions of the E1 and E3 regions. Genome-based expression vectors also containing a component 2 comprising an agent in the form of an expression vector incorporating an expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 - E1 and E3 A recombinant human adenovirus serotype 26 genome-based expression vector in which the region has been deleted and the ORF6-Ad26 region has been replaced by ORF6-Ad5, comprising: SEQ ID NO: 1, SEQ ID NO: 2, sequence Based on the genome of recombinant simian adenovirus serotype 25 containing the agent in the form of an expression vector in which an expression cassette selected from No. 3 is integrated and in which the E1 and E3 regions are deleted. which also contains a component 2 containing an agent in the form of an expression vector incorporating an expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3 - E1 and E3 regions deleted a recombinant simian adenovirus serotype 25 genome-based expression vector incorporating an expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3. SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, wherein the E1 and E3 regions are deleted and the recombinant human adenovirus serotype 5 genome-based expression vector containing component 1 comprising: which also contains component 2 which contains the agent in the form of an expression vector incorporating an expression cassette selected from

This patent also discloses the administration of the aforementioned variants of the agent for inducing specific immunity against severe acute respiratory syndrome SARS-CoV-2 virus, wherein component 1 and component 2 are: Effective doses are used consecutively with time intervals of at least one week.

It should be pointed out that this mode of administration has several drawbacks. Thus, for example, each of the components of a pharmaceutical product can cause side effects and allergic reactions, so the number of such events can increase when using a two-dose vaccination regimen. Moreover, such immunization regimens are associated with several practical difficulties, as it is necessary to ensure that the patient appears to receive the second dose after a certain time interval. Additionally, there are numerous logistical challenges associated with the timely delivery of the necessary drug components.

The field of the present invention thus leads to a need to expand the range of pharmaceutical agents capable of inducing an immune response to the SARS-CoV-2 virus among a wide range of populations.

The technical objective of the claimed group of inventions is to create a medicament containing a single active ingredient, while at the same time increasing the immune response to the SARS-CoV-2 virus among a broad spectrum of people. is to ensure effective induction of

DISCLOSURE OF THE INVENTION A solution to the technical problem is based on the genome of a recombinant strain of human adenovirus serotype 26 in which the E1 and E3 regions have been deleted and the ORF6-Ad26 region has been replaced by ORF6-Ad5. Severe acute respiratory syndrome virus SARS-CoV-, which contains as a single active component an expression vector incorporating an expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 2 is a liquid drug variant for inducing specific immunity to

Also, an expression vector based on the genome of a recombinant strain of human adenovirus serotype 5 in which the E1 and E3 regions are deleted, wherein the expression vector is selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 A liquid drug variant for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 has also been produced that contains an expression vector with an integrated cassette as the single active ingredient.

Further, an expression vector based on the genome of a recombinant strain of simian adenovirus serotype 25 in which the E1 and E3 regions are deleted, wherein the expression vector is selected from SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3 A variant of a liquid drug for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 is claimed which contains an expression vector with an integrated cassette as a single active ingredient.

Additionally, for certain implementations, the buffered solution of the drug due to its liquid state contains, in weight percent:
Tris 0,1831 to 0,3432
Sodium chloride 0,3313-0,6212
Sucrose 3,7821-7,0915
Magnesium chloride hexahydrate 0,0154-0,0289
EDTA 0,0029 to 0,0054
Polysorbate-80 0,0378-0,0709
Ethanol 95% 0,0004-0,0007
water rest.

Each of the drug variants is used to induce specific immunity against severe acute respiratory syndrome SARS-CoV-2 virus.

In that regard, the medicament is intended for intranasal or intramuscular administration. The agents can also be co-administered simultaneously by intranasal and intramuscular routes.

Further, for certain implementations, the agent is administered at a dose of 5 ^* 10 ¹⁰ to 5 ^* 10 ¹¹ viral particles by the intranasal route or at a dose of 5 ^* 10 ¹⁰ to 5 ^* 10 ¹¹ viral particles by the intramuscular route. administered. And for combined administration by intranasal and intramuscular routes, a dose of 5 ^* 10 ¹⁰ to 5 ^* 10 ¹¹ viral particles is administered intramuscularly and a dose of 5 ^* 10 ¹⁰ to 5 ^* 10 ¹¹ viral particles is administered intranasally. administered.

Combined administration contemplates intranasal and intramuscular administration within a single vaccination procedure.

The technical result is the creation of agents that ensure the development of humoral and cellular immune responses to the SARS-Cov-2 virus among a wide range of populations.

The primary purpose of immunization is to ensure effective and long-lasting protection against pathogens. One way to achieve this goal is to use multiple dose vaccine series. When the human body is first exposed to vaccine antigens, activation of two major components of the adaptive immune response occurs: B lymphocytes and effector T lymphocytes. After activation, B lymphocytes are transformed into plasma cells responsible for antibody production and also into memory B cells. Effector T lymphocytes are divided into two major types: helper T cells (CD4+) and cytotoxic (killer) T cells (CD8+). An important function of helper T cells is to facilitate the development of humoral and cell-mediated immune responses. The primary function of cytotoxic T cells is to kill damaged cells of the host. Killer T cells are believed to be one of the essential components of the antiviral immune response. However, after immunization, the number of antigen-specific immune cells declines with time, thus boosting doses are given. The latter allows the immune system to maintain adequate numbers of antigen-specific T cells and B cells (needed to ensure the body's defense against pathogens).

The development of single-component drugs capable of inducing sustainable immune responses following a single-dose immunization regimen is a complex research and practical challenge. However, it is difficult to overestimate the importance of such developments. A single vaccination dose can promote higher herd immunization rates, which is of great importance in pandemic situations. The drug may also be beneficial for emergency use and immunization of migratory populations of people (such as migratory tribes). In addition, it is noteworthy that there are fewer adverse events (such as injury rates and numbers of side effects and allergic reactions) associated with administration of single-dose drugs in humans.

Brief description of the drawing
Figure 3 illustrates the results of evaluating humoral immune responses to SARS-CoV-2 viral antigens in volunteers immunized with the liquid form of a development drug according to variant 1; Y-axis—IgG titers against the RBD of the SARS-CoV-2 S glycoprotein. X-axis - days. o IgG titers against the RBD of SARS-CoV-2 S glycoprotein on day 14 in each of the volunteers involved in the study □ SARS-CoV-2 S glycoprotein on day 21 in each of the volunteers involved in the study IgG titers against RBD of SARS-CoV-2 on day 28 in each of the volunteers involved in the study. shown. Statistically significant differences between day 14, day 21 and day 28 values are indicated by brackets and the Wilcoxon T-test p-values are displayed above. Figure 3 illustrates the results of evaluating humoral immune responses to SARS-CoV-2 viral antigens in volunteers immunized with the liquid form of a development drug according to variant 2; Y-axis—IgG titers against the RBD of the SARS-CoV-2 S glycoprotein. X-axis - days. o IgG titers against the RBD of SARS-CoV-2 S glycoprotein on day 14 in each of the volunteers involved in the study □ SARS-CoV-2 S glycoprotein on day 21 in each of the volunteers involved in the study IgG titers against RBD of SARS-CoV-2 on day 28 in each of the volunteers involved in the study. shown. Statistically significant differences between day 14, day 21 and day 28 values are indicated by brackets and the Wilcoxon T-test p-values are displayed above. Immunization in Volunteers Receiving Liquid Forms of Developed Agents According to Variant 1 as Estimated by the Percentage of Proliferating CD8+ (A) and CD4+ (B) Lymphocytes Restimulated with SARS-CoV-2 S-Antigen Explain the results of evaluating the efficacy of Y-axis - number of proliferating cells (%) X-axis - days. ○ (green) - symbol used to indicate the percentage of proliferative CD8+ on day 0 in each of the volunteers □ (green) - used to indicate the percentage of proliferative CD8+ on day 14 in each of the volunteers symbol △ (green) - symbol used to indicate the percentage of proliferative CD8+ on day 28 in each of the volunteers ○ (blue) - to indicate the percentage of proliferative CD4+ on day 0 in each of the volunteers Symbols used □ (blue)—symbols used to indicate the percentage of proliferative CD4+ on day 14 in each of the volunteers Δ (blue)—to indicate the percentage of proliferative CD4+ on day 28 in each of the volunteers The symbolic medians used for are indicated by black lines for each of the data groups. Statistically significant differences between values obtained on days 0, 14 and 28 are indicated by brackets and symbols ^* , p<0.05; ^** , p<0.01; ^**** , Indicated by p<0.001 (Mann-Whitney test). Immunization in Volunteers Receiving Liquid Forms of Developed Agents According to Variant 2 as Estimated by the Percentage of Proliferating CD8+ (A) and CD4+ (B) Lymphocytes Restimulated with SARS-CoV-2 S Antigen Explain the results of evaluating the efficacy of Y-axis - number of proliferating cells (%) X-axis - days. ○ (green) - symbol used to indicate the percentage of proliferative CD8+ on day 0 in each of the volunteers □ (green) - used to indicate the percentage of proliferative CD8+ on day 14 in each of the volunteers symbol △ (green) - symbol used to indicate the percentage of proliferative CD8+ on day 28 in each of the volunteers - symbol ○ (blue) - to indicate the percentage of proliferative CD4+ on day 0 in each of the volunteers Symbols used □ (blue)—symbols used to indicate the percentage of proliferative CD4+ on day 14 in each of the volunteers Δ (blue)—to indicate the percentage of proliferative CD4+ on day 28 in each of the volunteers The symbolic medians used for are indicated by black lines for each of the data groups. Statistically significant differences between values obtained on days 0, 14 and 28 are indicated by brackets and symbols ^* , p<0.05; ^** , p<0.01; ^**** , Indicated by p<0.001 (Mann-Whitney test).

Implementation of the Invention The active ingredient of the developed drug comprises an expression vector based on the genome of a recombinant adenovirus strain into which an expression cassette containing the gene for the SARS-CoV-2 antigen has been integrated.

Adenoviral vectors can enter many different human cell types, ensure high-level expression of target antigens, and help evade both humoral and cellular immune responses. The FSBI "NF Gamaleya NRCEM" of the Ministry of Health of the Russian Federation has developed three variants of mammalian adenovirus-based expression vectors:
- an expression vector based on the genome of a recombinant strain of human adenovirus serotype 26 in which the E1 and E3 regions have been deleted and the ORF6-Ad26 region replaced by ORF6-Ad5 - the E1 and E3 regions have been deleted - an expression vector based on the genome of a recombinant strain of simian adenovirus serotype 25 in which the E1 and E3 regions have been deleted, comprising , SEQ ID NO:4, SEQ ID NO:2, and SEQ ID NO:3.

SARS-CoV-2 viral surface S protein was selected as antigen. It is one of the most promising antigens capable of inducing strong and long-lasting immune responses. Antibodies to the S protein of SARS-CoV-2 were also demonstrated to have virus-neutralizing activity.

To maximize the immune response induced, the authors developed multiple variants of the expression cassette containing the S protein gene.

Expression cassette SEQ ID NO: 1 contains the CMV promoter, SARS-CoV-2 viral S protein gene, and polyadenylation signal. The CMV promoter is the promoter of the cytomegalovirus immediate-early gene that ensures constitutive expression in multiple cell types. However, the intensity of expression of target genes controlled by the CMV promoter varies between cell types. Furthermore, the level of transgene expression under the control of the CMV promoter was shown to decrease with increasing duration of cell culture. It is caused by suppression of gene expression related to DNA methylation [Wang W., Jia YL., Li YC., Jing CQ., Guo X., Shang XF., Zhao CP., Wang TY. mutation, and an enhancer on recombinant protein expression in CHO cells. // Scientific Reports - 2017. - Vol. 8. - P. 10416].

Expression cassette SEQ ID NO:2 contains the CAG promoter, SARS-CoV-2 viral S protein gene, and polyadenylation signal. The CAG promoter is a synthetic promoter containing the early enhancer of the CMV promoter, the chicken β-actin promoter and chimeric introns (chicken β-actin and rabbit β-globin). Experiments have demonstrated that the CAG promoter has higher transcriptional activity compared to the CMV promoter [Yang C.Q., Li X.Y., Li Q., Fu S.L., Li H., Guo Z.K., Lin J.T., Zhao S.T. Evaluation of three different promoters driving gene expression in developing chicken embryo by using in vivo electroporation. // Genet. Mol. Res. - 2014. - Vol. 13. - P. 1270-1277].

Expression cassette SEQ ID NO:3 contains the EF1 promoter, SARS-CoV-2 viral S protein gene, and polyadenylation signal. The EF1 promoter is the promoter of human eukaryotic translation elongation factor 1α (EF-1α). This promoter is constitutively active in a variety of cell types [Wang X, Xu Z, Tian Z, Zhang X, Xu D, Li Q, Zhang J, Wang T. The EF-1α promoter maintains high-level transgene 2017 Nov;21(11):3044-3054. doi: 10.1111/jcmm.13216. Epub 2017 May 30. PMID: 28557288; PMCID: PMC5661254.] . The EF-1α gene encodes elongation factor 1α, one of the most abundant proteins in eukaryotic cells, and exhibits expression in almost all mammalian cell types. The EF-1α promoter frequently demonstrates its activity in cells in which the viral promoter is unable to drive expression of the regulated gene and in cells in which the viral promoter is gradually lost.

Expression cassette SEQ ID NO:4 contains the CMV promoter, SARS-CoV-2 viral S protein gene, and polyadenylation signal.

Accordingly, the following three variants of the drug were developed as a result of the tasks achieved.
1) A liquid drug for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, wherein the E1 and E3 regions are deleted and the ORF6-Ad26 region is induced by ORF6-Ad5 An expression vector based on the genome of a recombinant strain of human adenovirus serotype 26 with replacement, comprising an expression vector incorporating an expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 A drug containing a single active ingredient.
2) A liquid drug for inducing specific immunity to severe acute respiratory syndrome virus SARS-CoV-2, which is a recombinant strain of human adenovirus serotype 5 lacking the E1 and E3 regions Agents containing a single active ingredient, including genome-based expression vectors that incorporate an expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3.
3) A liquid drug for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, which is a recombinant strain of simian adenovirus serotype 25 lacking the E1 and E3 regions Agents containing a single active ingredient, including genome-based expression vectors that incorporate an expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3.

The practice of the invention is demonstrated by the following examples:

Example 1. Manufacture of the active ingredient of a medicament for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, based on the genome of a recombinant strain of human adenovirus serotype 26. Three variants of the expression cassette were designed:
- the expression cassette SEQ ID NO: 1 contains the CMV promoter, the SARS-CoV-2 viral S protein gene and the polyadenylation signal;
- the expression cassette SEQ ID NO: 2 contains the CAG promoter, the SARS-CoV-2 viral S protein gene and the polyadenylation signal;
- The expression cassette SEQ ID NO:3 contains the EF1 promoter, the SARS-CoV-2 viral S protein gene and the polyadenylation signal.

Synthesis of the SARS-CoV-2 viral S protein gene was performed by "Eurogen" ZAO (Moscow).

To obtain recombinant strains of human adenovirus serotype 26, two plasmids manufactured at the FSBI "N. F. Gamaleya NRCEM" of the Ministry of Health of the Russian Federation were used: human adenovirus Recombinant human adenovirus serotype 26 with plasmid pAd26-Ends carrying homology arms of virus serotype 26 genome and open reading frame ORF6 of human adenovirus serotype 5 and deletion of E1 and E3 regions plasmid pAd26-too carrying the genome of

In the first stage of the study, genetic engineering techniques were used to construct plasmids containing the expression cassettes SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, respectively, and carrying the homology arms of the human adenovirus serotype 26 genome. Plasmids pAd26-Ends-CMV-S-CoV2, pAd26-Ends-CAG-S-CoV2, pAd26-Ends-EF1-S-CoV2 based on pAd26-Ends were obtained. The resulting plasmids were then linearized with unique hydrolysis sites and each plasmid was mixed with the recombinant vector pAd26-too. carrying the genome of recombinant human adenovirus serotype 26 with the open reading frame ORF6 of human adenovirus serotype 5 and a deletion of the E1 and E3 regions as a result of homologous recombination, the expression cassette SEQ ID NO: 1, Plasmids pAd26-too-CMV-S-CoV2, pAd26-too-CAG-S-CoV2, pAd26-too-EF1-S-CoV2 with SEQ ID NO:2 or SEQ ID NO:3 respectively were produced.

In the next step, the plasmids pAd26-too-CMV-S-CoV2, pAd26-too-CAG-S-CoV2, pAd26-too-EF1-S-CoV2 are hydrolyzed by specific restriction endonucleases to remove the vector parts. Removed. The resulting DNA product was used for transfection of HEK293 cell cultures.

Completed studies resulted in the following recombinant strains of human adenovirus serotype 26: Ad26-too-CMV-S-CoV2, Ad26-too-CAG-S-CoV2, Ad26-too-EF1- S-CoV2. A similar scheme was used to produce a control strain of human adenovirus serotype 26 that does not contain the SARS-CoV-2 S protein gene: Ad26-too.

Thus, containing the genome of recombinant human adenovirus serotype 26 with the E1 and E3 regions deleted and the ORF6-Ad26 region replaced by ORF6-Ad5, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: An expression vector incorporating an expression cassette selected from 3 was obtained. This expression vector is the active ingredient of the drug under development.

Example 2. Production of the Active Ingredient of a Drug for Inducing Specific Immunity Against Severe Acute Respiratory Syndrome Virus SARS-CoV-2 Based on the Genome of a Recombinant Strain of Human Adenovirus Serotype 5 Three Variants of the Expression Cassette was also used in this attempt:
- the expression cassette SEQ ID NO: 1 contains the CMV promoter, the SARS-CoV-2 viral S protein gene and the polyadenylation signal;
- the expression cassette SEQ ID NO: 2 contains the CAG promoter, the SARS-CoV-2 viral S protein gene and the polyadenylation signal;
- The expression cassette SEQ ID NO:3 contains the EF1 promoter, the SARS-CoV-2 viral S protein gene and the polyadenylation signal.

Synthesis of the SARS-CoV-2 viral S protein gene was performed by "Eurogen" ZAO (Moscow).

To obtain recombinant strains of human adenovirus serotype 5, the following two plasmids produced at the FSBI "NF Gamaleya NRCEM" of the Ministry of Health of the Russian Federation were used:
- a homology arm of the genome of adenovirus serotype 5 (one of the arms of homology is the beginning of the genome of human adenovirus serotype 5 (from the left inverted terminal repeat to the E1 region), and a virus containing the pIX protein The other homology arm contains the nucleotide sequence located after the ORF3 E4 region through the end of the genome).
- Plasmid pAd5-too carrying the genome of recombinant human adenovirus serotype 5 with deletion of the E1 and E3 regions.

In the first stage of the study, genetic engineering techniques were used to generate plasmids pAd5-Ends-CMV-S-CoV2, pAd5-Ends-CAG-S-CoV2, pAd5-Ends-CAG-S-CoV2, pAd5-Ends-EF1- based on plasmid pAd5-Ends. S-CoV2 was obtained. The plasmids produced contained the expression cassette SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, respectively, and carried homologous arms of the adenovirus serotype 5 genome. The resulting plasmids were then linearized with unique hydrolysis sites and each plasmid was mixed with the recombinant vector pAd5-too. As a result of homologous recombination, the plasmid pAd5-, which carries the genome of recombinant human adenovirus serotype 5 with deletion of the E1 and E3 regions, carries the expression cassette SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, respectively. too-CMV-S-CoV2, pAd5-too-CAG-S-CoV2, pAd5-too-EF1-S-CoV2 were produced.

In the next step, the plasmids pAd5-too-CMV-S-CoV2, pAd5-too-CAG-S-CoV2, pAd5-too-EF1-S-CoV2 are hydrolyzed by specific restriction endonucleases to remove the vector parts. Removed. The resulting DNA product was used for transfection of HEK293 cell cultures.

Completed studies resulted in the following recombinant strains of human adenovirus serotype 5: Ad5-too-CMV-S-CoV2, Ad5-too-CAG-S-CoV2, Ad5-too-EF1- S-CoV2. A similar scheme was used to produce a control strain of human adenovirus serotype 5 that does not contain the SARS-CoV-2 S protein gene: Ad5-too.

Thus, an expression vector containing a recombinant human adenovirus serotype 5 genome deleted for the E1 and E3 regions, which incorporates an expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 Got. This expression vector is the active ingredient of the drug under development.

Example 3. Manufacture of the active ingredient of a medicament for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 based on the genome of a recombinant strain of simian adenovirus serotype 25. Mutants used in this effort:
- the expression cassette SEQ ID NO: 4 contains the CMV promoter, the SARS-CoV-2 viral S protein gene and the polyadenylation signal;
- the expression cassette SEQ ID NO: 2 contains the CAG promoter, the SARS-CoV-2 viral S protein gene and the polyadenylation signal;
- The expression cassette SEQ ID NO:3 contains the EF1 promoter, the SARS-CoV-2 viral S protein gene and the polyadenylation signal.

Synthesis of the SARS-CoV-2 viral S protein gene was performed by "Eurogen" ZAO (Moscow).

To obtain recombinant strains of simian adenovirus serotype 25, the following two plasmids manufactured at the FSBI "NF Gamaleya NRCEM" of the Ministry of Health of the Russian Federation were used:
- the plasmid pSim25-Ends carrying the homology arms of the simian adenovirus serotype 25 genome
- Plasmid pSim25-null carrying the genome of recombinant simian adenovirus serotype 25 with deletion of the E1 and E3 regions.

In the first phase of the study, genetic engineering techniques were used to generate pSim25-Ends-based plasmids p-Sim25-Ends-CMV-S-CoV2, p-Sim25-Ends-CAG-S-CoV2, p-Sim25 -Ends-EF1-S-CoV2 was obtained. The plasmids produced contained the expression cassette SEQ ID NO: 4, SEQ ID NO: 2 or SEQ ID NO: 3, respectively, and carried homologous arms of the simian adenovirus serotype 25 genome. The resulting plasmids were then linearized with unique hydrolysis sites and each plasmid was mixed with the recombinant vector pSim25-too. As a result of homologous recombination, the plasmid pSim25-, which carries the genome of recombinant simian adenovirus serotype 25 with deletion of the E1 and E3 regions, carries the expression cassette SEQ ID NO: 4, SEQ ID NO: 2 or SEQ ID NO: 3, respectively. too-CMV-S-CoV2, pSim25-too-CAG-S-CoV2, pSim25-too-EF1-S-CoV2 were produced.

In the next step the plasmids pSim25-too-CMV-S-CoV2, pSim25-too-CAG-S-CoV2, pSim25-too-EF1-S-CoV2 are hydrolyzed by specific restriction endonucleases to remove the vector parts. Removed. The resulting DNA product was used for transfection of HEK293 cell cultures.

Completed studies resulted in the following recombinant strains of simian adenovirus serotype 25: simAd25-too-CMV-S-CoV2, simAd25-too-CAG-S-CoV2, simAd25-too-EF1- S-CoV2. A similar scheme was used to produce a control strain of simian adenovirus serotype 25 that does not contain the SARS-CoV-2 S protein gene: simAd25-too.

Thus, an expression containing the genome of a recombinant strain of simian adenovirus serotype 25 deleted for the E1 and E3 regions, which incorporates an expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3 A vector was obtained. This expression vector is the active ingredient of the drug under development.

Example 4. Buffer Solution Development We chose an aqueous buffer solution that ensures the stability of the recombinant adenoviral particles. Tris(hydroxymethyl)aminomethane (Tris) was added to the buffer to maintain the solution pH value. Addition of sodium chloride was necessary to reach the required ionic force and osmolarity. Sucrose was added as a cryoprotectant. Magnesium chloride hexahydrate was added as a divalent cation source. EDTA was added as an inhibitor of free radical oxidation, polysorbate-80 as a surfactant source, and ethanol 95% as an inhibitor of free radical oxidation.

In order to estimate the concentrations of the substances contained in the composition of the buffer solution for the liquid form of the drug, several variants of the experimental groups were made (Table 1). One of the active ingredients of the drug was added to each of the resulting buffered solutions:
1. An expression vector based on the genome of a recombinant strain of human adenovirus serotype 26 in which the E1 and E3 regions have been deleted and the ORF6-Ad26 region has been replaced by ORF6-Ad5, comprising an expression cassette SEQ ID NO: 1 (Ad26-CMV-S-CoV2, 1 ^* 10 ¹¹ viral particles)).
2. An expression vector based on the genome of a recombinant strain of human adenovirus serotype 5 in which the E1 and E3 regions are deleted and which incorporates the expression cassette SEQ ID NO: 1 (Ad5-CMV-S- CoV2, 1 ^* 10 ¹¹ viral particles).
3. An expression vector based on the genome of a recombinant strain of simian adenovirus serotype 25 in which the E1 and E3 regions are deleted and which incorporates the expression cassette SEQ ID NO: 4 (simAd25-CMV-S- CoV2, 1 ^* 10 ¹¹ viral particles).

The resulting agents were stored at temperatures of -18°C and -70°C for 3 months, then thawed and evaluated for changes in recombinant adenovirus titers.

The results of the experiments carried out demonstrated that after storage of the recombinant adenovirus for 3 months at temperatures of −18° C. and −70° C. in a buffer solution for the liquefaction of the drug, its titer did not change. .

Therefore, the buffer solution developed for the liquid form of the drug ensures the stability of all components of the developed drug in the following range of active moieties (mass %):
Tris: 0.1831% to 0.3432% by weight;
Sodium chloride: 0.3313% to 0.6212% by weight;
Sucrose: 3.7821% to 7.0915% by weight;
Magnesium chloride hexahydrate: 0.0154% to 0.0289% by mass;
EDTA: 0.0029% to 0.0054% by weight;
Polysorbate-80: 0.0378% to 0.0709% by weight;
Ethanol 95%: 0.0004% to 0.0007% by weight;
Solvent: rest.

Example 5. Manufacture of a medicament in liquid form for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 is an expression vector based on the genome of a recombinant strain of human adenovirus serotype 26, comprising an expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, in a buffer solution. Contains an integrated expression vector.

A liquid development drug for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 according to variant 2 is based on the genome of a recombinant strain of human adenovirus serotype 5 in a buffer solution. It contains an expression vector into which an expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 is integrated.

A liquid development drug for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 according to variant 3 is based on the genome of a recombinant strain of simian adenovirus serotype 25 in a buffer solution. The expression vector contains an expression vector into which an expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, and SEQ ID NO: 3 is integrated.

The active ingredient is mixed with the components of the buffer solution during the manufacturing process. Sterile vials are used to fill the medicinal product. Store in a dark place at temperatures below "minus" 18°C. Before use, it must be removed from the freezing chamber and kept at room temperature for no more than 30 minutes (until fully thawed). Prior to administration, the vial (ampule) should be mixed by gentle shaking. Do not shake the vial vigorously. Do not refreeze.

Example 6. Toxicity of developed agents after single intravenous and intramuscular administration to mice (acute toxicity)
This study was performed to assess the acute toxicity of the following agents:
- A liquid drug for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, wherein the E1 and E3 regions are deleted and the ORF6-Ad26 region is replaced by ORF6-Ad5 an expression vector based on the genome of a recombinant strain of human adenovirus serotype 26, comprising an expression vector incorporating an expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3; A medicament containing one active ingredient - a liquid medicament for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, human adenovirus serum lacking E1 and E3 regions A type 5 recombinant strain genome-based expression vector containing a single active ingredient comprising an expression vector integrated with an expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 - a liquid agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, which is a recombinant strain of simian adenovirus serotype 25 deleted in the E1 and E3 regions comprising a genome-based expression vector of SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3, which contains a single active ingredient.

In this study, 6-8 week old male and female outbred mice weighing 18-20 g were used.

Drug dose calculations were based on the immunizing dose (10 ⁸ vp) found in preliminary experiments with susceptible animal species—Syrian golden hamsters. The dose of mice was calculated according to their body weight. The lowest dose selected for toxicity studies in mice was the closest therapeutic dose of 10 ⁸ v.p. p. Met. No interspecies scaling factor was used for dose conversion. Dose was recalculated directly based on body weight according to WHO guidelines for vaccine preparation.

As a result, the following doses were selected for administration to mice in this experiment:
10 ⁸ v. p. - close to effective dose (ED) in mice;
10 ⁹ v. p. - 20 times higher than ED in mice;
10 ¹⁰ v. p. - 200 times higher than ED in mice;
10 ¹¹ v. p. - 2000 times higher than ED in mice;

Therefore, the following groups of experimental animals were formed:
1) Ad26-too-CMV-S-CoV2, 1 ^* 10 ⁸ v. p. , 20 mice;
2) Ad26-too-CMV-S-CoV2, 1 ^* 10 ⁹ v. p. , 20 mice;
3) Ad26-too-CMV-S-CoV2, 1 ^* 10 ¹⁰ v. p. , 20 mice;
4) Ad26-too-CMV-S-CoV2, 1 ^* 10 ¹¹ v. p. , 20 mice;
5) Ad5-too-CMV-S-CoV2, 1 ^* 10 ⁸ v. p. , 20 mice;
6) Ad5-too-CMV-S-CoV2, 1 ^* 10 ⁹ v. p. , 20 mice;
7) Ad5-too-CMV-S-CoV2, 1 ^* 10 ¹⁰ v. p. , 20 mice;
8) Ad5-too-CMV-S-CoV2, 1 ^* 10 ¹¹ v. p. , 20 mice;
9) simAd25-too-CMV-S-CoV2, 1 ^* 10 ⁸ _B v. p. , 20 mice;
10) simAd25-too-CMV-S-CoV2, 1 ^* 10 ⁹ v. p. , 20 mice;
11) simAd25-too-CMV-S-CoV2, 1 ^* 10 ¹⁰ v. p. , 20 mice;
12) simAd25-too-CMV-S-CoV2, 1 ^* 10 ¹¹ v. p. , 20 mice;
13) Placebo (buffer solution), 20 mice.

A physical examination of all animals was performed daily for 14 days to record signs of intoxication and the number of dead animals.

The following functional status parameters of experimental animals were recorded: activity, mobility, appearance, coat condition, eyes, ears, teeth and limbs. Physiological functions assessed included respiration, salivation, saliva, urine, and excretion.

All animals survived during the experiment. Animals from all groups appeared healthy, ate actively, had appropriate responses to stimuli, and showed interest in exploring the environment. The coat was thick, uniform, shiny, and close to the body, and no hair loss or brittleness was found. Muscle tone was not characterized by hypertonicity. There were no crusts, signs of inflammation or twitching in the outer ear. The tooth color was normal and the tooth did not crack. Mice were well nourished and did not suffer from malnutrition. Abdominal area was not dilated. Smooth breathing without difficulty. Salivation is normal. Voiding, urine color, gastrointestinal parameters, muscle tone, and reflexes are within normal physiological limits. The behavior of experimental animals did not differ from that of control animals.

On day 14 of the experiment, a planned euthanasia of mice was performed by cervical dislocation. During the course of the study, no critically ill animals were found with signs of inevitable death. Also, no animal deaths were reported.

A complete necropsy was performed on all animals. Necropsy includes the animal's physical condition, internal surfaces and vessels, cranial, thoracic, abdominal and pelvic cavities (including the internal organs and tissues of these cavities), the neck (including its organs and tissues), and the skeleton. An assessment of the skeletomuscular system was included.

Gross postmortem examination did not reveal any effect of the drug on the internal organs of the mice. No difference was found between control and experimental groups of animals. Weight gain did not differ between control and experimental groups of animals.

Example 7.
Evaluating Efficacy of Immunization with Developed Agents Based on Evaluation of Humoral Immune Response One of the key features of immunization efficacy is the antibody titer. This example elicits data on changes in antibody titers to the SARS-CoV-2 S protein 21 days after administration of drug to experimental animals.

Female mammalian species-BALB/c mice weighing 18 g were used in the experiments. All animals were divided into 13 groups of 5 animals per group and liquid development drug variants were injected intramuscularly at a dose of 5 ^* 10 ¹⁰ viral particles/200 μl.

Formed the following animal groups:
1) Ad26-too-CMV-S-CoV2
2) Ad26-too-CAG-S-CoV2
3) Ad26-too-EF1-S-CoV2
4) Ad26-too
5) Ad5-too-CMV-S-CoV2
6) Ad5-too-CAG-S-CoV2
7) Ad5-too-EF1-S-CoV2
8) Ad5-too
9) simAd25-too-CMV-S-CoV2
10) simAd25-too-CAG-S-CoV2
11) simAd25-too-EF1-S-CoV2
12) simAd25-too
13) placebo (buffer)

After 3 weeks, blood samples were taken from the tail vein of the animals and the serum was separated. Antibody titers were measured using an enzyme-linked immunosorbent assay (ELISA) according to the following protocol:
1) The antigen was adsorbed to the wells of a 96-well ELISA plate at a temperature of +4°C for 16 hours.
2) The plate was then "blocked" with 5% milk dissolved in non-specific signal blocking buffer in a volume of 100 μl per well to prevent non-specific binding. It was incubated for 1 hour on a shaker at 37°C.
3) Serum samples from immunized mice were diluted 100-fold and then a 2-fold dilution series was prepared. A total of 12 dilutions of each sample were prepared.
4) 50 μl of each diluted serum sample was added to the plate wells.
5) Next, incubation was carried out at 37°C for 1 hour.
6) After incubation, wells were washed three times with phosphate buffer.
7) A secondary antibody against mouse immunoglobulin conjugated with horseradish peroxidase was then added.
8) Next, incubation was performed at 37° C. for 1 hour.
9) After incubation, wells were washed three times with phosphate buffer.
10) A solution of tetramethylbenzidine (TMB), which is used as a substrate for horseradish peroxidase and converted into a colored compound by the reaction, was then added. The reaction was stopped after 15 minutes by the addition of sulfuric acid. The optical density (OD) of the solution was then measured at a wavelength of 450 nm in each well using a spectrophotometer.

Antibody titer was defined as the final dilution at which the optical density of the solution was significantly higher than the negative control group. The results obtained (geometric mean) are presented in Table 2.

Therefore, the experimental results demonstrate that all of the developed agents induce humoral immune responses against SARS-CoV-2.

Example 8. Evaluation of the immunogenicity of the developed drug by assessing humoral immune responses to SARS-CoV-2 viral antigens in the blood of volunteers at different time points after vaccination. The aim was to determine the strength of the immune response to SARS-CoV-2 viral antigens in the blood of volunteers at different time points after vaccination by type.

Healthy volunteers aged 18-60 were included in the trial. All participants in the trial were divided into several groups.
1) A liquid drug for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, wherein the E1 and E3 regions are deleted and the ORF6-Ad26 region is induced by ORF6-Ad5 An expression vector based on the genome of a recombinant strain of human adenovirus serotype 26 with permutation, containing a single active component comprising an expression vector incorporating an expression cassette selected from SEQ ID NO: 1 Drug, 10 ¹¹ viral particles/dose, 9 persons.
2) A liquid drug for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, wherein the E1 and E3 regions are deleted and the ORF6-Ad26 region is induced by ORF6-Ad5 A permuted human adenovirus serotype 5 recombinant strain genome-based expression vector containing a single active component comprising an expression vector that incorporates an expression cassette selected from SEQ ID NO: 1 Drug, 10 ¹¹ viral particles/dose, 9 persons.

Volunteers were immunized with a single intramuscular injection of the relevant drug.

Blood samples were taken from the subjects prior to immunization and on days 14, 21, 28 and 42. Serum was separated from the obtained blood samples and used to determine antibody titers against the SARS-CoV-2 viral S antigen.

Antibody titers were developed at the Ministry of Health of the Russian Federation FSBI "N. F. Gamaleya NRCEM" designed to determine IgG titers against the SARS-CoV-2 viral S protein RBD. was measured using a test kit (RZN 2020/10393 2020-05-18).

Plates pre-adsorbed with RBD (100 ng/well) were washed 5 times in wash buffer. Positive controls (100 μl) and negative controls (100 μl) were then added to plate wells in duplicate. Serial two-fold dilutions of study samples (two duplicates per sample) were added to the remaining plate wells. The plate was sealed with film and incubated at +37° C. for 1 hour with agitation at 300 rpm. The wells were then washed five times with a working solution of wash buffer. 100 μl of working solution of monoclonal antibody conjugate was then added to each well, the plate was closed with adhesive film and incubated for 1 hour at +37° C. with stirring at 300 rpm. The wells were then washed five times with a working solution of wash buffer. 100 μl of chromogenic substrate was then added to each well and incubated for 15 minutes at +20° C. in the dark. After this step, the reaction was stopped by adding 50 μl per well of stop reagent (1 M sulfuric acid solution). Results were recorded within 10 minutes of stopping the reaction by measuring the optical density in a spectrophotometer at a wavelength of 450 nm.

The IgG titer was defined as the highest serum dilution at which the OD450 value in the immunized subject's serum was two-fold higher than that in the control serum (subject's serum prior to immunization).

The results of evaluation of antibody titers against SARS-CoV-2 antigen in serum of volunteers after administration of different variants of the development drug are shown in FIGS.

As demonstrated by the figure, immunization of volunteers with both variants of the development drug resulted in potent (control non-immunized volunteers) characterized by elevated antibody titers against the SARS-CoV-2 viral S protein. It provides the achievement of humoral immunity that is statistically significantly different from the values in the group). In that regard, the intensity of the humoral immune response increased with each passing day from the day of immunization.

Example 9. Evaluation of the immunogenicity of the developed drug by assessing cellular immune responses to SARS-CoV-2 viral antigens in the blood of volunteers at different time points after vaccination. The aim was to determine the strength of the immune response to SARS-CoV-2 viral antigens in the blood of volunteers after immunization with type.

Healthy volunteers aged 18-60 were included in the trial. All participants in the trial were divided into several groups.
1) A liquid drug for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, wherein the E1 and E3 regions are deleted and the ORF6-Ad26 region is induced by ORF6-Ad5 An expression vector based on the genome of a recombinant strain of human adenovirus serotype 26 with permutation, containing a single active component comprising an expression vector incorporating an expression cassette selected from SEQ ID NO: 1 Drug, 10 ¹¹ viral particles/dose, 9 persons.
2) A liquid drug for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, wherein the E1 and E3 regions are deleted and the ORF6-Ad26 region is induced by ORF6-Ad5 A permuted human adenovirus serotype 5 recombinant strain genome-based expression vector containing a single active component comprising an expression vector that incorporates an expression cassette selected from SEQ ID NO: 1 Drug, 10 ¹¹ viral particles/dose, 9 persons.

Volunteers were immunized with a single intramuscular injection of the relevant drug.

Blood samples were taken from the subjects before immunization and on days 14 and 28 after immunization. Mononuclear cells were separated from the samples by density gradient centrifugation in Ficoll solution (1.077 g/mL; PanEco). The detached cells were then stained with the fluorescent dye CFSE (Invivogen, USA) and placed in wells of a 96-well plate (2 ^{* 105} cells/well). As a next step, lymphocytes were restimulated in vitro by adding coronavirus S protein to the medium (final protein concentration - 1 μg/ml). Intact cells without added antigen were used as a negative control. The percentage of proliferating cells was measured 72 hours after antigen addition and the medium was sampled for gamma-interferon measurement.

To determine the % of proliferating cells, these were treated with T lymphocytes CD3, CD4, CD8 (anti-CD3 Pe-Cy7 (BD Biosciences, clone SK7), anti-CD4 APC (BD Biosciences, clone SK3), anti-CD8 PerCP - Stained with an antibody against the marker molecule Cy5.5 (BD Biosciences, clone SK1)). The high performance cytofluorometer BD FACS Aria III (BD Biosciences, USA) was used to determine proliferating cells (with lower amounts of CFSE dye) CD4+ and CD8+ T lymphocytes in the cell mixture. The percentage of proliferating cells obtained in each specimen was determined by subtracting the results obtained in the analysis of intact cells from the results obtained in the analysis of cells restimulated with coronavirus S antigen. This finding is illustrated in FIGS.

The results of the studies conducted showed that the strength of cell-mediated immunity (based on the median number of proliferating CD4+ and CD8+ T lymphocytes) induced by immunization of volunteers with different drug variants was greater than that from the day of immunization. It was proven to increase as the days went by. Peak values of proliferating CD4+ and CD8+ T lymphocytes were recorded 28 days after immunization in all groups. A maximum statistically significant difference in proliferating CD4+ and CD8+ T lymphocyte values was reported between values on day 0 and day 28 of the study (p<0.001).

Therefore, based on the above findings, immunization with the developed agent produces potent antigen-specific cellular anti-infective immunity evidenced by high levels of statistical significance in parameters measured before and after immunization. It can be concluded that

Example 10. Evaluation of Adverse Events in Volunteers After Single and Double Dose Immunization with Developmental Drug Variants The purpose of this study was to determine adverse events in volunteers after immunization with different drug variants. rice field.

Healthy volunteers aged 18-60 were included in the trial. All participants in the trial were divided into several groups.
1) Single intramuscular administration of liquid recombinant human adenovirus serotype 26-based drug (Ad26-too-CMV-S-CoV2), 10 ¹¹ viral particles/dose, 9 people.
2) Single intramuscular administration of liquid recombinant human adenovirus serotype 5-based drug (Ad5-too-CMV-S-CoV2), 10 ¹¹ viral particles/dose, 9 persons.
3) Initially, a liquid recombinant human adenovirus serotype 26-based agent (Ad26-too-CMV-S-CoV2) (10 ¹¹ viral particles/dose) was administered and after 21 days the liquid Two-dose immunization regimen, 20 people receiving a recombinant human adenovirus serotype 5-based agent (Ad5-too-CMV-S-CoV2) (10 ¹¹ viral particles/dose).

Table 3 contains data for the most common adverse events reported from the start of the study by visit (telephone) on Day 180 in the study.

As demonstrated by the data presented, the incidence of side effects following a single-dose regimen of immunization with liquid development agents to induce specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 was , was significantly lower compared to the two-dose immunization regimen.

Example 11. Evaluation of the Efficacy of Intranasal Immunization with Developed Agents Based on Evaluation of Humoral Immune Responses The purpose of this study was to verify the efficacy of the developed agents after being administered intranasally.

18-20 g female C57/B16 mice were used in the experiment, 5/group. Formed the following animal groups:
1) Single intranasal administration of liquid recombinant human adenovirus serotype 26-based drug (Ad26-too-CMV-S-CoV2), 5 ^* 10 ¹⁰ viral particles/dose.
2) Single intranasal administration of liquid recombinant human adenovirus serotype 5-based drug (Ad5-too-CMV-S-CoV2), 5 ^* 10 ¹⁰ viral particles/dose.
3) Single intranasal administration of liquid recombinant simian adenovirus serotype 25-based drug (simAd25-too-CMV-S-CoV2), 5 ^* 10 ¹⁰ viral particles/dose.
4) Single intranasal administration of liquid recombinant human adenovirus serotype 26-based drug (Ad26-too-CMV-S-CoV2), 5 ^* 10 ¹¹ viral particles/dose.
5) Single intranasal administration of liquid recombinant human adenovirus serotype 5-based drug (Ad5-too-CMV-S-CoV2), 5 ^* 10 ¹¹ viral particles/dose.
6) Single intranasal administration of liquid recombinant simian adenovirus serotype 25-based drug (simAd25-too-CMV-S-CoV2), 5 ^* 10 ¹¹ viral particles/dose.
7) Single intranasal administration of buffer solution (negative control).

After 3 weeks, blood samples were taken from the tail vein of the animals and the serum was separated. Antibody titers were measured using an enzyme-linked immunosorbent assay (ELISA) according to the following protocol:
1) The antigen was adsorbed to the wells of a 96-well ELISA plate at a temperature of +4°C for 16 hours.
2) The plate was then "blocked" with 5% milk dissolved in TPBS in a volume of 100 μl per well to prevent non-specific binding. It was incubated for 1 hour on a shaker at 37°C.
3) Serum samples from immunized mice were diluted 100-fold and then a 2-fold dilution series was prepared.
4) 50 μl of each diluted serum sample was added to the plate wells.
5) Next, incubation was carried out at 37°C for 1 hour.
6) After incubation, wells were washed three times with phosphate buffer.
7) A secondary antibody against mouse immunoglobulin conjugated with horseradish peroxidase was then added.
8) Next, incubation was performed at 37° C. for 1 hour.
9) After incubation, wells were washed three times with phosphate buffer.
10) A solution of tetramethylbenzidine (TMB), which is used as a substrate for horseradish peroxidase and converted into a colored compound by the reaction, was then added. The reaction was stopped after 15 minutes by the addition of sulfuric acid. The optical density (OD) of the solution was then measured at a wavelength of 450 nm in each well using a spectrophotometer.

Antibody titers were determined as the last dilution at which the optical density of the solution was significantly higher than the negative control. The results obtained (geometric mean) are presented in Table 5.

As shown by the experimental results, intranasal immunization of animals with the developed drug resulted in increased antibody titers against the S protein of SARS-CoV-2. Thus, the results of this experiment demonstrate that liquid development agents administered by the intranasal route can be used to induce specific immunity against severe acute respiratory syndrome virus SARS-CoV-2.

Example 12. Evaluation of Immunogenicity of Developed Agents After Combined Intramuscular and Intranasal Immunizations The purpose of this study was to verify the efficacy of developed agents after combined intramuscular and intranasal immunizations.

18-20 g female C57/B16 mice were used in the experiment, 5/group. Formed the following animal groups:
1) simultaneous intranasal administration of liquid recombinant human adenovirus serotype 26-based agent (Ad26-too-CMV-S-CoV2) (5 ^* 10 ¹⁰ viral particles/dose) and liquid Intramuscular administration of recombinant human adenovirus serotype 26-based drug (Ad26-too-CMV-S-CoV2) (5 ^* 10 ¹⁰ viral particles/dose) 2) Recombinant human adenovirus serotype 26 in liquid form based drug (Ad26-too-CMV-S-CoV2) (5 ^* 10 ¹⁰ viral particles/dose) 3) liquid recombinant human adenovirus serotype 26 based drug (Ad26- too-CMV-S-CoV2) (5 ^* 10 ¹⁰ viral particles/dose) 4) concurrent liquid recombinant human adenovirus serotype 5-based drug (Ad5-too-CMV- S-CoV2) (5 ^* 10 ¹⁰ viral particles/dose) and a liquid recombinant human adenovirus serotype 5-based drug (Ad5-too-CMV-S-CoV2) (5 ^* 10 5) intramuscular administration of liquid recombinant human adenovirus serotype 5-based agent (Ad5-too-CMV-S-CoV2) (5 ^{* 10 10 viral} particles/dose) intranasally. internal administration,
6) intramuscular administration of a liquid recombinant human adenovirus serotype 5-based agent (Ad5-too-CMV-S-CoV2) (5 ^* 10 ¹⁰ viral particles/dose); Intranasal administration of recombinant simian adenovirus serotype 25-based drug (simAd25-too-CMV-S-CoV2) (5 ^* 10 ¹⁰ viral particles/dose) and liquid recombinant simian adenovirus serotype 25 based drug (simAd25-too-CMV-S-CoV2) (5 ^* 10 ¹⁰ viral particles/dose) 8) liquid recombinant simian adenovirus serotype 25-based drug (simAd25- too-CMV-S-CoV2) (5 ^* 10 ¹⁰ viral particles/dose) 9) Recombinant simian adenovirus serotype 25-based drug in liquid form (simAd25-too-CMV-S-CoV2) (5 ^* 10 ¹⁰ viral particles/dose) intramuscular administration 10) Concomitant liquid recombinant human adenovirus serotype 26-based drug (Ad26-too-CMV-S-CoV2) (5 ^* 10 ¹¹ viral particles/dose) and intramuscular administration of a liquid recombinant human adenovirus serotype 26-based drug (Ad26-too-CMV-S-CoV2) (5 ^* 10 ¹¹ viral particles/dose). 11) Intranasal administration of liquid recombinant human adenovirus serotype 26-based drug (Ad26-too-CMV-S-CoV2) (5 ^* 10 ¹¹ viral particles/dose) 12) Liquid recombinant Intramuscular administration of a human adenovirus serotype 26-based agent (Ad26-too-CMV-S-CoV2) (5 ^* 10 ¹¹ viral particles/dose) 13) Concomitant liquid recombinant human adenovirus serum Intranasal administration of type 5-based drug (Ad5-too-CMV-S-CoV2) (5 ^* 10 ¹¹ viral particles/dose) and liquid recombinant human adenovirus serotype 5-based drug ( Ad5-too-CMV-S-CoV2) (5 ^* 10 ¹¹ viral particles/dose) intramuscularly 14) Liquid recombinant human adenovirus serotype 5-based drug (Ad5-too-CMV-S- CoV2) intranasal administration of (5 ^* 10 ¹¹ viral particles/dose) 15) liquid recombinant human adenoviral blood Intramuscular administration of serotype 5-based agent (Ad5-too-CMV-S-CoV2) (5 ^* 10 ¹¹ viral particles/dose) 16) Concomitant liquid recombinant simian adenovirus serotype 25 Intranasal administration of base drug (simAd25-too-CMV-S-CoV2) (5 ^* 10 ¹¹ viral particles/dose) and liquid recombinant simian adenovirus serotype 25-based drug (simAd25-too -CMV-S-CoV2) (5 ^* 10 ¹¹ viral particles/dose) 17) Liquid recombinant simian adenovirus serotype 25-based drug (simAd25-too-CMV-S-CoV2) ( 18) Liquid recombinant simian adenovirus serotype 25-based drug (simAd25-too-CMV-S-CoV2) (5 ^{* 10 11 viral} particles/dose) ^. 19) Concurrent intranasal administration of buffer solution and intramuscular administration of buffer solution (negative control)
20) Intranasal administration of buffer solution (negative control)
21) Intramuscular administration of buffer solution (negative control)

After 3 weeks, blood samples were taken from the tail vein of the animals and the serum was separated. Antibody titers were measured using an enzyme-linked immunosorbent assay (ELISA) according to the following protocol:
1) The antigen was adsorbed to the wells of a 96-well ELISA plate at a temperature of +4°C for 16 hours.
2) The plate was then "blocked" with 5% milk dissolved in TPBS in a volume of 100 μl per well to prevent non-specific binding. It was incubated for 1 hour on a shaker at 37°C.
3) Serum samples from immunized mice were diluted 100-fold and then a 2-fold dilution series was prepared.
4) 50 μl of each diluted serum sample was added to the plate wells.
5) Next, incubation was carried out at 37°C for 1 hour.
6) After incubation, wells were washed three times with phosphate buffer.
7) A secondary antibody against mouse immunoglobulin conjugated with horseradish peroxidase was then added.
8) Next, incubation was performed at 37° C. for 1 hour.
9) After incubation, wells were washed three times with phosphate buffer.
10) A solution of tetramethylbenzidine (TMB), which is used as a substrate for horseradish peroxidase and converted into a colored compound by the reaction, was then added. The reaction was stopped after 15 minutes by the addition of sulfuric acid. The optical density (OD) of the solution was then measured at a wavelength of 450 nm in each well using a spectrophotometer.

Antibody titer was defined as the final dilution at which the optical density of the solution was significantly higher than the negative control group. The results obtained (geometric mean) are presented in Table 5.

As indicated by the results obtained, combined intranasal and intramuscular immunization of animals with the developed agents induced stronger humoral immune responses compared to immunization by a single route of administration. Thus, the results of this experiment demonstrate that the developed agents can be used to induce specific immunity against the SARS-CoV-2 virus by intramuscular and intranasal combination and co-administration.

Industrial Applicability All examples provided demonstrate the efficacy and industrial applicability of pharmaceuticals that ensure effective induction of immune responses against the SARS-CoV-2 virus.

Claims (8)

A liquid drug for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, wherein the E1 and E3 regions are deleted and the ORF6-Ad26 region is replaced by ORF6-Ad5 an expression vector based on the genome of a recombinant strain of human adenovirus serotype 26 comprising an expression vector incorporating an expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 A drug containing the active ingredient of A liquid agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, wherein the genome of a recombinant strain of human adenovirus serotype 5 lacking the E1 and E3 regions is Agents containing a single active ingredient, including expression vectors based on which expression cassettes selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 are integrated. A liquid agent for inducing specific immunity to severe acute respiratory syndrome virus SARS-CoV-2, wherein the genome of a recombinant strain of simian adenovirus serotype 25 lacking the E1 and E3 regions is Agents containing a single active ingredient, including expression vectors based on which expression cassettes selected from SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3 are integrated. in % by mass:
Tris 0,1831 to 0,3432
Sodium chloride 0,3313-0,6212
Sucrose 3,7821-7,0915
Magnesium chloride hexahydrate 0,0154-0,0289
EDTA 0,0029 to 0,0054
Polysorbate-80 0,0378-0,0709
Ethanol 95% 0,0004-0,0007
A medicament according to any one of claims 1 to 3, characterized in that it additionally contains a buffer solution comprising the remainder of the water. Use of an agent according to any one of claims 1 to 3 for inducing an immune response against the SARS-CoV-2 virus, wherein said agent is administered intranasally or intramuscularly, or intranasally and intramuscularly Uses claimed for intra-combined administration. Use according to claim 5, characterized in that the medicament is claimed for intranasal administration at a dose of 5 ^* 10 ¹⁰ to 5 ^* 10 ¹¹ viral particles. Use according to claim 5, characterized in that the medicament is claimed for intramuscular administration at a dose of 5 ^* 10 ¹⁰ to 5 ^* 10 ¹¹ virus particles. For combined intranasal and intramuscular administration, the drug is administered intramuscularly at a dose of 5 ^* 10 ¹⁰ to 5 ^* 10 ¹¹ viral particles and intranasally at a dose of 5 ^* 10 ¹⁰ to 5 ^* 10 ¹¹ viral particles. 6. Use according to claim 5, characterized in that it is administered to

Images